Last reviewed · How we verify
piperacillin continuous infusion
Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including pneumonia, intra-abdominal infections, and sepsis, Hospital-acquired infections caused by susceptible gram-negative and gram-positive organisms.
At a glance
| Generic name | piperacillin continuous infusion |
|---|---|
| Sponsor | University Hospital, Ghent |
| Drug class | Beta-lactam antibiotic (ureidopenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is an extended-spectrum ureidopenicillin that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and causing cell wall lysis. When administered as a continuous infusion, it maintains sustained bactericidal concentrations at the infection site, optimizing time-dependent killing. This delivery method is particularly effective for serious infections caused by gram-negative and gram-positive bacteria.
Approved indications
- Serious bacterial infections including pneumonia, intra-abdominal infections, and sepsis
- Hospital-acquired infections caused by susceptible gram-negative and gram-positive organisms
Common side effects
- Diarrhea
- Nausea
- Rash
- Phlebitis at infusion site
- Hypersensitivity reactions
- Seizures (in renal impairment)
Key clinical trials
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (PHASE3)
- Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
- BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia (PHASE4)
- Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia (PHASE4)
- Are Standard Dosing Regimens of Piperacillin-Tazobactam Suitable in Critically Ill Patients With Open Abdomen and Negative Pressure Wound Therapy? A Population Pharmacokinetic Study.
- Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- piperacillin continuous infusion CI brief — competitive landscape report
- piperacillin continuous infusion updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI